Multiply Labs, a robotics company focused on biomanufacturing, has integrated NVIDIA’s Isaac and GR00T technologies into its systems. The move aims to improve the efficiency and scalability of cell and gene therapy production.

Cell and gene therapies are complex treatments that can be challenging to manufacture at scale. Multiply Labs is developing robotic biomanufacturing systems designed to increase consistency, traceability, and operational efficiency in existing facilities.

The company’s current system uses four parallel-operating robotic arms to maximise output. According to the company, its new system can produce up to 100 times more patient doses per square foot than conventional clean space manual processes.

NVIDIA’s Isaac Sim technology is being used to create high-fidelity digital twins of Multiply Labs’ systems. This approach enables the company to simulate new hardware and test automation strategies before deployment.

Foundation models from NVIDIA’s GR00T open robot infrastructure are also being explored for training manipulation behaviours relevant to biomanufacturing. Perception pipelines, using NVIDIA FoundationPose and FoundationStereo, will convert expert demonstrations into training data.

Fred Parietti, co-founder and CEO of Multiply Labs, said: “the company is investing in cutting-edge robotic technologies” and combining them with NVIDIA’s infrastructure to accelerate development and unlock scalability.